Risperidone sustained release microsphere composition
A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
1. A pharmaceutical composition comprising:
a pharmaceutically active component selected from risperidone or a salt thereof, 9-hydroxy risperidone or a salt thereof; and
a polymer blend consisting of a first uncapped poly(lactide-co-glycolide) and a second uncapped poly(lactide-co-glycolide), wherein the first uncapped poly(lactide-co-glycolide) has a molar ratio of lactide to glycolide of 65:35 to 90:10; and the second uncapped poly(lactide-co-glycolide) has a molar ratio of lactide to glycolide of 50:50 to 75:25; and
wherein the pharmaceutical composition is prepared by forming a plurality of microspheres, each microspheres consisting of the pharmaceutically active component encapsulated in the polymer blend.
2. The pharmaceutical composition according to claim 1 , wherein the second uncapped poly(lactide-co-glycolide) has a molar ratio of lactide to glycolide of 50:50.
3. The pharmaceutical composition according to claim 1 , wherein forming the plurality of microspheres comprises the steps of:
a) dissolving the active agent and the polymer blend in an organic solvent to form a mixture;
b) combining the mixture with an aqueous solution comprising a water soluble polymer for emulsification;
c) removing the organic solvent to provide a residue;
d) washing and filtering the residue to obtain the microspheres.
4. The pharmaceutical composition according to claim 3 , wherein a concentration of the polymer blend in the organic solvent is from 70mg/ml to 160mg/ml.
5. The pharmaceutical composition according to claim 4 , wherein the concentration of the polymer blend in the organic solvent is from 80mg/ml to 140mg/ml.
6. The pharmaceutical composition according to claim 5 , wherein the concentration of the polymer blend in the organic solvent is from 90mg/ml to 120mg/ml.
7. The pharmaceutical composition according to claim 6 , wherein the concentration of the polymer blend in the organic solvent is 90mg/ml.
8. The pharmaceutical composition according to claim 3 , wherein the mixture is combined with the aqueous solution through a homogenizer at a rotation speed of about 380 rpm.
9. The pharmaceutical composition according to claim 3 , wherein the volume ratio between the organic solvent and the aqueous solution is 1:100.
10. The pharmaceutical composition according to claim 3 , wherein the organic solvent is dichloromethane, and wherein the water soluble polymer is polyvinyl alcohol.
11. The pharmaceutical composition according to claim 4 , wherein the first uncapped poly(lactide-co-glycolide) has an intrinsic viscosity of 0.4-0.9 dl/g, and the second uncapped poly(lactide-co-glycolide) has an intrinsic viscosity of 0.1-0.35 dl/g.
12. The pharmaceutical composition according to claim 11 wherein the first uncapped poly(lactide-co-glycolide) has an intrinsic viscosity of 0.45-0.8 dl/g; and the second uncapped poly(lactide-co-glycolide) has an intrinsic viscosity of 0.1-0.3 dl/g.
13. The pharmaceutical composition according to claim 12 wherein the first uncapped poly(lactide-co-glycolide) has an intrinsic viscosity of 0.45-0.55 dl/g; and the second uncapped poly(lactide-co-glycolide) has an intrinsic viscosity of 0.2-0.3 dl/g.
14. The pharmaceutical composition according to claim 4 , wherein the first uncapped poly(lactide-co-glycolide) has a weight average molecular weight of 50,000-145,000, and the second uncapped poly(lactide-co-glycolide) has a weight average molecular weight of 4,000-45,000.
15. The pharmaceutical composition according to claim 14 wherein the first uncapped poly(lactide-co-glycolide) has a weight average molecular weight of 55,000-110,000; and the second uncapped poly(lactide-co-glycolide) has a weight average molecular weight of 4,000-35,000.
16. The pharmaceutical composition according to claim 15 wherein the first uncapped poly(lactide-co-glycolide) has a weight average molecular weight of 55,000-85,000; and the second uncapped poly(lactide-co-glycolide) has a weight average molecular weight of 15,000-35,000.
17. The pharmaceutical composition according to claim 4 , wherein the first uncapped poly(lactide-co-glycolide) is present in the polymer blend at 50-95 wt % and the second uncapped poly(lactide-co-glycolide) is present in the polymer blend at 5-50 wt %.
18. The pharmaceutical composition according to claim 17 , wherein the first uncapped poly(lactide-co-glycolide) is present in the polymer blend at 70-90 wt % and the second uncapped poly(lactide-co-glycolide) is present in the polymer blend at 10-30 wt %.
19. The pharmaceutical composition according to claim 18 , wherein the first uncapped poly(lactide-co-glycolide) is present in the polymer blend at 80 wt % and the second uncapped poly(lactide-co-glycolide) is present in the polymer blend at 20 wt %.
20. The pharmaceutical composition according to claim 4 , wherein a weight content of the pharmaceutically active component in the microspheres is within a range from 10% to 60%; and a weight content of the polymer blend in the microspheres is within a range from 40% to 90%.
21. The pharmaceutical composition according to claim 20 , wherein a weight content of the pharmaceutically active component in the microspheres is within a range of 35%-55%; and a weight content of the polymer blend in the microspheres is within a range of 45%-65%.
22. The pharmaceutical composition according to claim 21 , wherein a weight content of the pharmaceutically active component in the microspheres is within a range of 40% -50%; and a weight content of the polymer blend in the microspheres is within a range of 50% -60%.